Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Astrazeneca Plc ADR (NQ: AZN ) 86.66 +0.77 (+0.90%) Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 3,336,033 Open 86.22 Bid (Size) 86.53 (1) Ask (Size) 86.77 (4) Prev. Close 85.89 Today's Range 85.86 - 86.88 52wk Range 60.47 - 86.88 Shares Outstanding N/A Dividend Yield 1.07% Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News AstraZeneca Threatens To Move Vaccine Production Amid Reduced State Support August 23, 2024 AstraZeneca may relocate its vaccine manufacturing site from Merseyside to Philadelphia as the UK government considers slashing state aid from £90 million to £40 million, jeopardizing Britain's life... Via Benzinga Biotech Bull Market: 3 Ways To Play It August 20, 2024 Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. Via Talk Markets Topics Economy Exposures Interest Rates Performance YTD +26.70% +26.70% 1 Month +8.72% +8.72% 3 Month +10.34% +10.34% 6 Month +31.64% +31.64% 1 Year +27.65% +27.65% More News Read More Ozempic And Wegovy Linked to Increased Suicidal Thoughts In Observational Study, But Results Are Contested August 20, 2024 Via Benzinga Johnson & Johnson Strikes $1.7B Deal To Acquire Heart-Tech Innovator V-Wave August 20, 2024 Via Benzinga Exposures Product Safety 10 Health Care Stocks Whale Activity In Today's Session August 19, 2024 Via Benzinga Is NASDAQ:AZN a Suitable Choice for Quality Investing? August 14, 2024 Via Chartmill FDA Approves AstraZeneca's Blockbuster Cancer Drug, Imfinzi, In Combination With Chemo For Non-Small Cell Lung Cancer August 16, 2024 Via Benzinga Exposures Product Safety IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery August 16, 2024 From AstraZeneca Via Business Wire Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations August 15, 2024 Via Investor's Business Daily IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US August 15, 2024 From AstraZeneca Via Business Wire AstraZeneca's $578M Vaccine Plant In Doubt As UK Government Cuts Funding August 14, 2024 Via Benzinga Defying the Market: 3 Mega-Cap Stocks Soaring to New Highs August 14, 2024 Via MarketBeat Topics ETFs 3 Pharmaceutical Stocks That Can Surge Higher Even if The Markets Correct August 14, 2024 Via InvestorPlace Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows August 13, 2024 Via Benzinga Exposures COVID-19 New European Regulations Could Hinder Rare Disease Treatments, Pharma Industry Raises Concerns Over Stricter Clinical Trial Rules August 13, 2024 Via Benzinga Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows August 13, 2024 Via Benzinga Exposures COVID-19 EXCLUSIVE: Penny Stock Conduit Pharmaceuticals Inks Licensing Pact With AstraZeneca For Multiple Assets August 08, 2024 Via Benzinga Top Analyst Reports For AstraZeneca, TotalEnergies & ConocoPhillips August 07, 2024 Via Talk Markets Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data August 05, 2024 Via Benzinga Here's What AstraZeneca's CEO Has to Say About the Weight Loss Drugs Market August 04, 2024 Via The Motley Fool Bank Of England Reduces 16-Year High Interest Rates In Divided Decision As Inflation Hits 2% August 01, 2024 Via Benzinga Topics Economy Exposures Interest Rates Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? July 31, 2024 Via InvestorPlace Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations July 30, 2024 Via Benzinga Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial July 29, 2024 From AstraZeneca Via Business Wire UK Agency Says AstraZeneca's Breast Cancer Drug Enhertu Is Expensive, CEO Pascal Soriot Urges Review Of Drug Pricing Assessment July 26, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.